Latest / The Vox Markets Podcast
2008: hVIVO Year in Review: Milestones, Growth and 2025 Ambitions
In our recent interview with Mo Khan, CEO of hVIVO, we reflected on the company’s outstanding achievements in 2024 and gained insights into its ambitious roadmap for 2025. Under Mo’s leadership, hVIVO has solidified its position as a global leader in human challenge trials, achieving record revenues, expanding its client base, and leveraging its cutting-edge clinical trial models to accelerate drug and vaccine development.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.